Objective:

To evaluate the association between the remnant cholesterol-inflammation index (RCII) and the risk of major adverse cardiovascular events (MACE) in patients with angina undergoing percutaneous coronary intervention (PCI).

Approach:

Key Findings:

• Each standard deviation increase in RCII was associated with a 5% higher MACE risk (HR = 1.05, 95%CI: 1.04–1.07).
• Hazard ratios for MACE risk in the second and third tertiles of RCII were 2.87 (95%CI: 2.03–4.04) and 4.42 (95%CI: 3.09–6.32), respectively.
• RCII was significantly associated with MACE risk across various subgroups without significant interactions.
• RCS analysis indicated a non-linear positive association (P for non-linearity < 0.001).
• Time-dependent ROC analysis showed moderate discriminatory ability with AUCs ranging from 0.739 to 0.786 over 30 months.

Interpretation:

Baseline RCII may serve as a potential clinical biomarker for assessing the risk of new-onset MACE in patients with angina undergoing PCI.

Conclusion:

The study suggests that RCII could be a useful indicator for MACE risk in this patient population.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.